Jordan - English - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

مستودع أدوية العمد - al-amad drug store - nicotine 39.37 mg - 39.37 mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

magnesium 39.5mg (1.6mmol)) capsules (special order - magnesium glycerophosphate - oral capsule - 39.5mg

United States - English - NLM (National Library of Medicine)

ncs healthcare of ky, llc dba vangard labs - atorvastatin calcium propylene glycol solvate (unii: yrz789owmi) (atorvastatin - unii:a0jwa85v8f) - therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. drug therapy is recommended as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. in patients with chd or multiple risk factors for chd, atorvastatin calcium tablets can be started simultaneously with diet. in adult patients without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as age, smoking, hypertension, low hdl-c, or a family history of early coronary heart disease, atorvastatin calcium tablets are indicated to: - reduce the risk of myocardial infarction - reduce the risk of stroke - reduce the risk for revascularization procedures and angina in adult patients with type 2 diabetes, and without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as retinopathy, albuminuria, smoking, or hypertension, atorvastatin calcium tablets are indicated to: - reduce the risk of myocardial infarction - reduce the risk of stroke  in adult patients with clinically evident coronary heart disease, atorvastatin calcium tablets are indicated to: - reduce the risk of non-fatal myocardial infarction - reduce the risk of fatal and non-fatal stroke - reduce the risk for revascularization procedures - reduce the risk of hospitalization for chf - reduce the risk of angina   atorvastatin calcium tablets are indicated: - as an adjunct to diet to reduce elevated total-c, ldl-c, apo b, and tg levels and to increase hdl-c in adult patients with primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia (fredrickson types iia and iib); - as an adjunct to diet for the treatment of adult patients with elevated serum tg levels (fredrickson type iv); - for the treatment of adult patients with primary dysbetalipoproteinemia (fredrickson type iii) who do not respond adequately to diet; - to reduce total-c and ldl-c in patients with homozygous familial hypercholesterolemia (hofh) as an adjunct to other lipid-lowering treatments (e.g., ldl apheresis) or if such treatments are unavailable; - as an adjunct to diet to reduce total-c, ldl-c, and apo b levels in pediatric patients, 10 years to 17 years of age, with heterozygous familial hypercholesterolemia (hefh) if after an adequate trial of diet therapy the following findings are present: a. ldl-c remains ≥ 190 mg/dl or b. ldl-c remains ≥ 160 mg/dl and: a. ldl-c remains ≥ 190 mg/dl or b. ldl-c remains ≥ 160 mg/dl and: - there is a positive family history of premature cardiovascular disease or - two or more other cvd risk factors are present in the pediatric patient atorvastatin calcium tablets have not been studied in conditions where the major lipoprotein abnormality is elevation of chylomicrons ( fredrickson types i and v). - active liver disease, which may include unexplained persistent elevations in hepatic transaminase levels - hypersensitivity to any component of this medication - pregnancy  [see use in specific populations (8.1, 8.3)] . - lactation  [see use in specific populations (8.2)] . risk summary atorvastatin calcium is contraindicated for use in pregnant women since safety in pregnant women has not been established and there is no apparent benefit of lipid lowering drugs during pregnancy. because hmg-coa reductase inhibitors decrease cholesterol synthesis and possibly the synthesis of other biologically active substances derived from cholesterol, atorvastatin calcium may cause fetal harm when administered to a pregnant woman.  atorvastatin calcium should be discontinued as soon as pregnancy is recognized [see contraindications (4)] . limited published data on the use of atorvastatin are insufficient to determine a drug-associated risk of major congenital malformations or miscarriage. in animal reproduction studies in rats and rabbits there was no evidence of embryo-fetal toxicity or congenital malformations at doses up to 30 and 20 times, respectively, the human exposure at the maximum recommended human dose (mrhd) of 80 mg, based on body surface area (mg/m2 ). in rats administered atorvastatin during gestation and lactation, decreased postnatal growth and development was observed at doses ≥ 6 times the mrhd (see data) . the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. data human data limited published data on atorvastatin calcium from observational studies, meta-analyses and case reports have not shown an increased risk of major congenital malformations or miscarriage. rare reports of congenital anomalies have been received following intrauterine exposure to other hmg-coa reductase inhibitors. in a review of approximately 100 prospectively followed pregnancies in women exposed to simvastatin or lovastatin, the incidences of congenital anomalies, spontaneous abortions, and fetal deaths/stillbirths did not exceed what would be expected in the general population. the number of cases is adequate to exclude a ≥3 to 4-fold increase in congenital anomalies over the background incidence. in 89% of the prospectively followed pregnancies, drug treatment was initiated prior to pregnancy and was discontinued at some point in the first trimester when pregnancy was identified.  animal data atorvastatin crosses the rat placenta and reaches a level in fetal liver equivalent to that of maternal plasma. atorvastatin was administered to pregnant rats and rabbits during organogenesis at oral doses up to 300 mg/kg/day and 100 mg/kg/day, respectively. atorvastatin was not teratogenic in rats at doses up to 300 mg/kg/day or in rabbits at doses up to 100 mg/kg/day. these doses resulted in multiples of about 30 times (rat) or 20 times (rabbit) the human exposure at the mrhd based on surface area (mg/m2 ). in rats, the maternally toxic dose of 300 mg/kg resulted in increased post-implantation loss and decreased fetal body weight. at the maternally toxic doses of 50 and 100 mg/kg/day in rabbits, there was increased post-implantation loss, and at 100 mg/kg/day fetal body weights were decreased. in a study in pregnant rats administered 20, 100, or 225 mg/kg/day from gestation day 7 through to lactation day 20 (weaning), there was decreased survival at birth, postnatal day 4, weaning, and post-weaning in pups of mothers dosed with 225 mg/kg/day, a dose at which maternal toxicity was observed. pup body weight was decreased through postnatal day 21 at 100 mg/kg/day, and through postnatal day 91 at 225 mg/kg/day. pup development was delayed (rotarod performance at 100 mg/kg/day and acoustic startle at 225 mg/kg/day; pinnae detachment and eye-opening at 225 mg/kg/day). these doses correspond to 6 times (100 mg/kg) and 22 times (225 mg/kg) the human exposure at the mrhd, based on auc. risk summary atorvastatin calcium use is contraindicated during breastfeeding [see contraindications (4)] . there is no available information on the effects of the drug on the breastfed infant or the effects of the drug on milk production. it is not known whether atorvastatin is present in human milk, but it has been shown that another drug in this class passes into human milk and atorvastatin is present in rat milk. because of the potential for serious adverse reactions in a breastfed infant, advise women that breastfeeding is not recommended during treatment with atorvastatin calcium. contraception atorvastatin calcium may cause fetal harm when administered to a pregnant woman. advise females of reproductive potential to use effective contraception during treatment with atorvastatin calcium [see use in specific populations (8.1)] . heterozygous familial hypercholesterolemia (hefh) the safety and effectiveness of atorvastatin calcium have been established in pediatric patients, 10 years to 17 years of age, with hefh as an adjunct to diet to reduce total cholesterol, ldl-c, and apo b levels when, after an adequate trial of diet therapy, the following are present: - ldl-c ≥ 190 mg/dl, or - ldl-c ≥ 160 mg/dl and a positive family history of fh, or premature cvd in a first, or second-degree relative, or two or more other cvd risk factors are present. - a positive family history of fh, or premature cvd in a first, or second-degree relative, or - two or more other cvd risk factors are present. use of atorvastatin calcium for this indication is supported by evidence from [see dosage and administration (2.2), adverse reactions (6.1), clinical pharmacology (12.3), and clinical studies (14.6)] : - a placebo-controlled clinical trial of 6 months duration in 187 boys and postmenarchal girls, 10 years to 17 years of age. patients treated with 10 mg or 20 mg daily atorvastatin calcium had an adverse reaction profile generally similar to that of patients treated with placebo. in this limited controlled study, there was no significant effect on growth or sexual maturation in boys or on menstrual cycle length in girls. a three year open-label uncontrolled trial that included 163 pediatric patients 10 to 15 years of age with hefh who were titrated to achieve a target ldl-c < 130 mg/dl. the safety and efficacy of atorvastatin calcium in lowering ldl-c appeared generally consistent with that observed for adult patients, despite limitations of the uncontrolled study design advise postmenarchal girls of contraception recommendations, if appropriate for the patient [see use in specific populations (8.1), (8.3)] .   the long-term efficacy of atorvastatin calcium therapy initiated in childhood to reduce morbidity and mortality in adulthood has not been established.   the safety and efficacy of atorvastatin calcium have not been established in pediatric patients younger than 10 years of age with hefh. homozygous familial hypercholesterolemia (hofh) clinical efficacy of atorvastatin calcium with dosages up to 80 mg/day for 1 year was evaluated in an uncontrolled study of patients with hofh including 8 pediatric patients [see clinical studies (14.5)] . of the 39,828 patients who received atorvastatin calcium in clinical studies, 15,813 (40%) were ≥65 years old and 2,800 (7%) were ≥75 years old. no overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older adults cannot be ruled out. since advanced age (≥65 years) is a predisposing factor for myopathy, atorvastatin calcium should be prescribed with caution in the elderly. atorvastatin calcium is contraindicated in patients with active liver disease which may include unexplained persistent elevations in hepatic transaminase levels [see contraindications (4) and clinical pharmacology (12.3) ] .

United States - English - NLM (National Library of Medicine)

ncs healthcare of ky, inc dba vangard labs - galantamine hydrobromide (unii: mj4ptd2vvw) (galantamine - unii:0d3q044kca) - galantamine 4 mg - galantamine tablets are indicated for the treatment of mild to moderate dementia of the alzheimer's type. galantamine tablets are contraindicated in patients with known hypersensitivity to galantamine hydrobromide or to any excipients used in the formulation.

United States - English - NLM (National Library of Medicine)

actavis pharma, inc. - ipratropium bromide (unii: j697uz2a9j) (ipratropium - unii:gr88g0i6ul), albuterol sulfate (unii: 021sef3731) (albuterol - unii:qf8svz843e) - ipratropium bromide anhydrous 0.5 mg in 3 ml - ipratropium bromide and albuterol sulfate inhalation solution is indicated for the treatment of bronchospasm associated with copd in patients requiring more than one bronchodilator. ipratropium bromide and albuterol sulfate inhalation solution is contraindicated in patients with a history of hypersensitivity to any of its components, or to atropine and its derivatives. ipratropium bromide and albuterol sulfate inhalation solution 0.5 mg/3 mg per 3 ml  read this patient information completely every time your prescription is filled as information may have changed. keep these instructions with your medication as you may want to read them again. ipratropium bromide and albuterol sulfate inhalation solution should only be used under the direction of a physician. your physician and pharmacist have more information about ipratropium bromide and albuterol sulfate inhalation solution and the condition for which it has been prescribed. contact them if you have additional questions. storing your medicine store ipratrop

United States - English - NLM (National Library of Medicine)

ncs healthcare of ky, inc dba vangard labs - sotalol hydrochloride (unii: hec37c70xx) (sotalol - unii:a6d97u294i) - sotalol hydrochloride 80 mg - sotalol hydrochloride tablets, usp are indicated for the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that in the judgment of the physician are life-threatening. because of the proarrhythmic effects of sotalol hydrochloride tablets, usp (see warnings ), including a 1.5 to 2% rate of torsade de pointes or new vt/vf in patients with either nsvt or supraventricular arrhythmias, its use in patients with less severe arrhythmias, even if the patients are symptomatic, is generally not recommended. treatment of patients with asymptomatic ventricular premature contractions should be avoided. initiation of sotalol hydrochloride treatment or increasing doses, as with other antiarrhythmic agents used to treat life-threatening arrhythmias, should be carried out in the hospital. the response to treatment should then be evaluated by a suitable method (e.g., pes or holter monitoring) prior to continuing the patient on chronic therapy. various approaches have been used to determi

United States - English - NLM (National Library of Medicine)

ncs healthcare of ky, inc dba vangard labs - azathioprine (unii: mrk240iy2l) (azathioprine - unii:mrk240iy2l) - azathioprine 50 mg - azathioprine tablets usp are indicated as an adjunct for the prevention of rejection in renal homotransplantation. it is also indicated for the management of active rheumatoid arthritis to reduce signs and symptoms. azathioprine tablets usp are indicated as an adjunct for the prevention of rejection in renal homotransplantation. experience with over 16,000 transplants shows a 5-year patient survival of 35% to 55%, but this is dependent on donor, match for hla antigens, anti-donor or anti-b-cell alloantigen antibody, and other variables. the effect of azathioprine on these variables has not been tested in controlled trials. azathioprine tablets usp are indicated for the treatment of active rheumatoid arthritis (ra) to reduce signs and symptoms. aspirin, non-steroidal anti-inflammatory drugs and/or low dose glucocorticoids may be continued during treatment with azathioprine. the combined use of azathioprine with disease modifying anti-rheumatic drugs (dmards) has not been studied for either added benefit or une

United States - English - NLM (National Library of Medicine)

ncs healthcare of ky, llc dba vangard labs - diltiazem hydrochloride (unii: olh94387te) (diltiazem - unii:ee92bbp03h) - diltiazem hydrochloride 30 mg - diltiazem hydrochloride tablets usp are indicated for the management of chronic stable angina and angina due to coronary artery spasm. diltiazem is contraindicated in: - patients with sick sinus syndrome except in the presence of a functioning ventricular pacemaker - patients with second- or third-degree av block except in the presence of a functioning ventricular pacemaker - patients with hypotension (less than 90 mm hg systolic) - patients who have demonstrated hypersensitivity to the drug - patients with acute myocardial infarction and pulmonary congestion documented by x-ray on admission

United States - English - NLM (National Library of Medicine)

ncs healthcare of ky, inc dba vangard labs - diltiazem hydrochloride (unii: olh94387te) (diltiazem - unii:ee92bbp03h) - diltiazem hydrochloride 120 mg - diltiazem hydrochloride extended-release capsules, usp are indicated for the treatment of hypertension. it may be used alone or in combination with other antihypertensive medications. diltiazem hydrochloride extended-release capsules, usp are indicated for the management of chronic stable angina and angina due to coronary artery spasm. diltiazem hydrochloride is contraindicated in (1) patients with sick sinus syndrome except in the presence of a functioning ventricular pacemaker, (2) patients with second-or third-degree av block except in the presence of a functioning ventricular pacemaker, (3) patients with hypotension (less than 90 mm hg systolic), (4) patients who have demonstrated hypersensitivity to the drug, and (5) patients with acute myocardial infarction and pulmonary congestion documented by x-ray on admission.

United States - English - NLM (National Library of Medicine)

ncs healthcare of ky, inc dba vangard labs - diltiazem hydrochloride (unii: olh94387te) (diltiazem - unii:ee92bbp03h) - diltiazem hydrochloride 120 mg - diltiazem hydrochloride extended-release capsules, usp are indicated for the treatment of hypertension. it may be used alone or in combination with other antihypertensive medications. diltiazem hydrochloride extended-release capsules, usp are indicated for the management of chronic stable angina and angina due to coronary artery spasm. diltiazem hydrochloride is contraindicated in (1) patients with sick sinus syndrome except in the presence of a functioning ventricular pacemaker, (2) patients with second-or third-degree av block except in the presence of a functioning ventricular pacemaker, (3) patients with hypotension (less than 90 mm hg systolic), (4) patients who have demonstrated hypersensitivity to the drug, and (5) patients with acute myocardial infarction and pulmonary congestion documented by x-ray on admission.